Top 3 Tremfya Manufacturers (2026 Audit Report)

H2: Market Trends for Tremfya in 2026

As we enter the second half (H2) of 2026, several key market trends are shaping the commercial and clinical landscape for Tremfya (guselkumab), Janssen’s IL-23 inhibitor used primarily in moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA). These trends reflect evolving competition, payer dynamics, regulatory developments, and shifting treatment paradigms.

1. Intensified Competition in the IL-23 and Psoriasis Market

By H2 2026, the dermatology and rheumatology markets continue to see growing competition, particularly from newer IL-23 and IL-17 inhibitors. Key competitors such as:
– Skyrizi (risankizumab, AbbVie)
– Ilumya (tildrakizumab, Sun Pharma)
– Siliq (brodalumab, Valeant)
– Cosentyx (secukinumab, Novartis) and Taltz (ixekizumab, Eli Lilly) in the IL-17 class

are capturing significant market share due to strong safety profiles, convenient dosing, and aggressive rebating strategies. Tremfya maintains a strong position due to its proven long-term efficacy and favorable safety data, but faces pricing pressure, especially in the U.S. commercial insurance and Medicare Part D segments.

2. Expansion into Psoriatic Arthritis Driving Growth

Tremfya’s approval and growing adoption in psoriatic arthritis (PsA) continue to be a major growth driver in H2 2026. With increasing physician confidence in its dual dermatological and rheumatological benefits, Tremfya is being positioned earlier in treatment algorithms—especially for PsA patients with concomitant skin involvement. Real-world evidence (RWE) studies published in 2025–2026 support its structural benefit and inhibition of radiographic progression, enhancing its appeal over TNF inhibitors in select patients.

3. Payer Access and Formulary Positioning Challenges

Despite clinical strengths, Tremfya faces tightening formulary access in the U.S. due to:
– Increased use of prior authorization (PA) and step therapy requirements.
– Preference for biosimilars and lower-cost biologics in managed care plans.
– Rebating wars with rivals like Skyrizi, which often secure preferred status through higher rebates.

Janssen has responded with value-based contracting and patient support programs, but net pricing remains under pressure, affecting overall revenue growth.

4. Growing Emphasis on Oral and Topical Alternatives

The rise of oral therapies such as deucravacitinib (Sotyktu, Bristol Myers Squibb) presents a new challenge. As a once-daily TYK2 inhibitor, Sotyktu appeals to patients seeking non-injectable options. Although Tremfya leads in long-term efficacy and durability, deucravacitinib’s convenience is influencing treatment decisions, especially in mild-to-moderate psoriasis patients who previously might have been considered for biologics.

5. Global Market Expansion and Emerging Markets

Outside the U.S. and EU, Janssen is focusing on expanding Tremfya’s footprint in Asia-Pacific (particularly Japan and South Korea) and Latin America, where biologic penetration in psoriasis and PsA is still growing. Regulatory approvals and partnerships with local distributors are accelerating uptake, supported by regional clinical data and pricing strategies tailored to healthcare infrastructure.

6. Biosimilar Threat on the Horizon

Although no biosimilar to guselkumab has launched by H2 2026, the patent cliff is approaching (expected 2027–2028 in key markets). As a result, Janssen is proactively investing in lifecycle management, including exploring new indications (e.g., Crohn’s disease, where phase 3 trials are ongoing) and combination therapies to extend clinical relevance and delay biosimilar erosion.

---

Conclusion:
In H2 2026, Tremfya remains a clinically trusted option in the IL-23 inhibitor class, particularly for patients with both skin and joint manifestations. However, its market growth is tempered by competitive intensity, payer restrictions, and the rise of oral alternatives. Janssen’s success will depend on differentiation through real-world outcomes, expansion into new indications, and strategic pricing in a rapidly evolving biologic and small-molecule landscape.

Common Pitfalls Sourcing Tremfya (Quality, IP)

Sourcing Tremfya (guselkumab), a biologic medication developed by Janssen for autoimmune conditions like plaque psoriasis and Crohn’s disease, involves significant risks related to quality and intellectual property (IP). Being aware of these pitfalls is crucial for healthcare providers, patients, and procurement professionals.

Quality Risks

• Counterfeit Products: Unauthorized suppliers may offer counterfeit versions of Tremfya that lack the correct active ingredient, contain harmful impurities, or do not meet sterility standards, posing serious health risks.
• Improper Storage and Handling: Biologics like Tremfya require strict cold-chain logistics. Sourcing from unreliable vendors may result in exposure to temperature variations, compromising drug efficacy and safety.
• Lack of Regulatory Approval: Products sourced from unregulated markets may not have undergone evaluation by agencies like the FDA or EMA, meaning their safety, purity, and potency are unverified.
• Expired or Near-Expiry Stock: Illicit suppliers may distribute expired or soon-to-expire products to cut costs, reducing treatment effectiveness.

Intellectual Property (IP) Concerns

• Patent Infringement: Tremfya is protected by patents covering its composition, method of use, and manufacturing processes. Sourcing biosimilars or unauthorized versions before patent expiry may lead to legal liability.
• Unauthorized Biosimilars: While biosimilars are emerging, only those approved by regulatory authorities and compliant with IP laws should be considered. Unapproved biosimilars may infringe on Janssen’s IP and lack proven equivalence.
• Gray Market Distribution: Purchasing through unauthorized distributors may involve diverted products originally intended for other markets, violating territorial IP rights and distribution agreements.

Avoiding these pitfalls requires sourcing exclusively through authorized distributors, verifying regulatory approvals, and ensuring compliance with local and international IP laws.

Logistics & Compliance Guide for Tremfya (guselkumab)

This guide provides essential information on the logistics and regulatory compliance considerations for the distribution, handling, storage, and administration of Tremfya (guselkumab), a human monoclonal antibody used for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and ulcerative colitis.

Product Overview and Regulatory Status

Tremfya (guselkumab) is an interleukin-23 (IL-23) inhibitor approved by regulatory authorities including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health agencies. It is indicated for adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active ulcerative colitis, depending on regional approvals. Ensure all usage complies with the approved label in the specific country of distribution.

Storage and Handling Requirements

Tremfya must be stored under strict temperature control to maintain product integrity. The recommended storage conditions are:

• Temperature: Refrigerate unopened pre-filled syringes and autoinjectors at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.
• Freezing: Do not freeze. Discard if frozen.
• Exposure to Light: Protect from direct sunlight and artificial light by keeping in the original packaging until use.
• In-Use Stability: Once removed from refrigeration, Tremfya can be kept at room temperature (up to 25°C or 77°F) for a single period of up to 30 days. Do not return to the refrigerator after removal. Discard if not used within this timeframe or if exposed to temperatures outside the acceptable range.

Transportation and Distribution

Transportation of Tremfya must adhere to cold chain logistics standards to ensure temperature integrity:

• Use validated cold chain packaging with temperature monitoring devices (e.g., data loggers).
• Maintain temperatures between 2°C and 8°C throughout transit.
• Shipments must comply with Good Distribution Practices (GDP) as defined by regulatory bodies such as the FDA and EMA.
• Distributors and wholesalers must be authorized and compliant with local pharmaceutical distribution regulations.
• Temperature excursions must be documented and assessed for potential product impact per quality management procedures.

Prescription and Dispensing Controls

Tremfya is a prescription-only medication and must be dispensed in accordance with national regulations:

• Must be prescribed by a licensed healthcare provider with appropriate training in managing autoimmune diseases.
• Pharmacists must verify prescription validity and patient eligibility, including prior treatment history and contraindications.
• Dispensing records must be maintained per local legal requirements, including patient name, prescriber, dosage, quantity, and date.

Risk Evaluation and Mitigation Strategy (REMS) or Equivalent

While Tremfya does not currently require a U.S. FDA-mandated REMS program, healthcare providers and pharmacies must adhere to product-specific risk management protocols, including:

• Screening patients for latent tuberculosis (TB) and hepatitis B before initiating treatment.
• Monitoring for hypersensitivity reactions, infections, and adverse events during therapy.
• Reporting adverse events to the appropriate pharmacovigilance system (e.g., FDA MedWatch, EudraVigilance).

Import and Export Compliance

International shipment of Tremfya requires compliance with import/export regulations:

• Obtain necessary import licenses and permits from destination country health authorities.
• Ensure all packaging includes proper labeling in the local language, with batch number, expiration date, and storage instructions.
• Comply with the World Health Organization (WHO) Guidelines for Good Distribution Practices and regional regulations such as the EU Falsified Medicines Directive (FMD).
• Track and trace systems must be in place to prevent counterfeit distribution.

Recordkeeping and Audit Readiness

Maintain comprehensive records for a minimum of 5–10 years (per local regulations), including:

• Batch-specific storage and transport temperature logs.
• Distribution records (shipper, recipient, quantities, dates).
• Adverse event reports and pharmacovigilance documentation.
• Training records for personnel handling the product.
• Audit trails for any temperature excursions or deviations.

Regular internal audits and readiness for regulatory inspections are essential.

Patient Support and Adherence Programs

Authorized patient support programs may be offered to assist with:

• Insurance verification and reimbursement support.
• Injection training and educational materials.
• Reminders for dosing schedules.
  Ensure all patient support activities comply with privacy laws (e.g., HIPAA in the U.S., GDPR in the EU) and promotional regulations.

Disposal and Returns

• Do not reuse pre-filled syringes or autoinjectors.
• Dispose of used devices according to local biohazard waste regulations.
• Do not accept returns of expired or temperature-compromised products. Follow manufacturer’s return and destruction procedures for unused product.

Training and Compliance Oversight

All personnel involved in the handling, distribution, or administration of Tremfya must receive regular training on:

• Product-specific handling and storage.
• GDP and pharmacovigilance requirements.
• Regulatory compliance and reporting obligations.
  A designated compliance officer or quality assurance team should oversee adherence to this guide and applicable regulations.

For the most current information, refer to the official prescribing information and regulatory updates from the manufacturer (Janssen Biotech, Inc.) and relevant health authorities.

Declaration: Companies listed are verified based on web presence, factory images, and manufacturing DNA matching. Scores are algorithmically calculated.